Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry

Eur J Cancer. 2009 Dec;45(18):3220-7. doi: 10.1016/j.ejca.2009.08.020. Epub 2009 Sep 18.

Abstract

Aim: Presenting features, treatment and outcome of 134 newborns with neuroblastoma diagnosed over a 27-year period are described.

Methods: Analyses were performed on the entire cohort and on patients distributed over three periods of diagnosis.

Results: Twenty-seven tumours (20.1%) were detected prenatally. Localised disease prevailed (65.7%) with an increase of stage 1 patients over time from 18.8% to 46.5%. Disseminated disease accounted for 34.3% of tumours with only one stage 4 and 45 stage 4S. Five-year overall survival (OS) of the entire cohort was 88.3%. Five/88 patients with localised disease died, including three who died of complications (OS, 95.3%). The only stage 4 patient survived. Eleven/45 stage 4S patients died, including 7/18 symptomatic and 4/27 asymptomatic (OS, 74.1%).

Conclusion: The outcome of neuroblastoma in newborns is excellent. In localised tumours, surgery-related deaths outnumbered deaths due to disease. Symptomatic stage 4S patients were at greater risk of dying.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers / analysis
  • Carboplatin / administration & dosage
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Gene Amplification
  • Humans
  • Infant
  • Infant, Newborn
  • Italy / epidemiology
  • Male
  • Neoplasm Staging
  • Neuroblastoma / diagnosis
  • Neuroblastoma / epidemiology*
  • Neuroblastoma / pathology
  • Neuroblastoma / therapy
  • Pregnancy
  • Prenatal Diagnosis
  • Registries*
  • Survival Rate
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Biomarkers
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Carboplatin